Recruitment and activation of type 3 innate lymphoid cells promote antitumor immune responses
暂无分享,去创建一个
B. Ryffel | F. Végran | R. Boidot | F. Ghiringhelli | C. Paget | C. Rébé | T. Baranek | M. Bruchard | F. Chalmin | Elise Ballot | C. Truntzer | Christophe Hibos | C. Paul | Emilie Barsac | Mannon Geindreau | Cindy Racoeur | Anaïs Perrichet | Fanny Chalmin
[1] F. Ghiringhelli,et al. Interleukin-1β and Cancer , 2020, Cancers.
[2] N. Frahm,et al. CXCR3 enables recruitment and site-specific bystander activation of memory CD8+ T cells , 2019, Nature Communications.
[3] Shasha Liu,et al. Colorectal cancer cell-derived CCL20 recruits regulatory T cells to promote chemoresistance via FOXO1/CEBPB/NF-κB signaling , 2019, Journal of Immunotherapy for Cancer.
[4] R. García-Becerra,et al. Calcitriol Inhibits the Proliferation of Triple-Negative Breast Cancer Cells through a Mechanism Involving the Proinflammatory Cytokines IL-1β and TNF-α , 2019, Journal of immunology research.
[5] J. Kelsen,et al. Innate lymphoid cells support regulatory T cells in the intestine through interleukin-2 , 2019, Nature.
[6] S. Mattarollo,et al. The Role of CXCR3 and Its Chemokine Ligands in Skin Disease and Cancer , 2018, Front. Med..
[7] R. Eri,et al. Modulation of the CCR6-CCL20 Axis: A Potential Therapeutic Target in Inflammation and Cancer , 2018, Medicina.
[8] K. Hirakawa,et al. Significance of tumor‐infiltrating lymphocytes before and after neoadjuvant therapy for rectal cancer , 2018, Cancer science.
[9] B. Becher,et al. Tissue microenvironment dictates the fate and tumor-suppressive function of type 3 ILCs , 2017, The Journal of experimental medicine.
[10] T. Gajewski,et al. Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. , 2017, Cancer cell.
[11] J. Kelsen,et al. Transient inhibition of ROR-γt therapeutically limits intestinal inflammation by reducing TH17 cells and preserving group 3 innate lymphoid cells , 2016, Nature Medicine.
[12] Pablo Tamayo,et al. Compendium of Immune Signatures Identifies Conserved and Species-Specific Biology in Response to Inflammation. , 2016, Immunity.
[13] S. Motoyama,et al. CXCL10 Expression Status is Prognostic in Patients with Advanced Thoracic Esophageal Squamous Cell Carcinoma , 2016, Annals of Surgical Oncology.
[14] E. Voronov,et al. IL-1 in Colon Inflammation, Colon Carcinogenesis and Invasiveness of Colon Cancer , 2015, Cancer Microenvironment.
[15] L. Moretta,et al. NCR+ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures , 2015, Nature Communications.
[16] P. Romero,et al. CD127+ innate lymphoid cells are dysregulated in treatment naïve acute myeloid leukemia patients at diagnosis , 2015, Haematologica.
[17] D. Dombrowicz,et al. CD3bright signals on γδ T cells identify IL‐17A‐producing Vγ6Vδ1+ T cells , 2015, Immunology and cell biology.
[18] R. Emerson,et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.
[19] B. Blom,et al. Activated innate lymphoid cells are associated with a reduced susceptibility to graft-versus-host disease. , 2014, Blood.
[20] Mark S. Sundrud,et al. Small-molecule RORγt antagonists inhibit T helper 17 cell transcriptional network by divergent mechanisms. , 2014, Immunity.
[21] Y. Belkaid,et al. Microbiota-Dependent Crosstalk Between Macrophages and ILC3 Promotes Intestinal Homeostasis , 2014, Science.
[22] Y. Bang,et al. Clinical Implications of VEGF, TGF-β1, and IL-1β in Patients with Advanced Non-small Cell Lung Cancer , 2013, Cancer research and treatment : official journal of Korean Cancer Association.
[23] F. Powrie,et al. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model , 2013, The Journal of experimental medicine.
[24] J. Furuse,et al. Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer , 2013, British Journal of Cancer.
[25] X. Chen,et al. IL-1 enhances expansion, effector function, tissue localization, and memory response of antigen-specific CD8 T cells , 2013, The Journal of experimental medicine.
[26] Wilfrid Boireau,et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth , 2012, Nature Medicine.
[27] Dan R. Littman,et al. Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORγt activity , 2011, Nature.
[28] Toshihiro Ito,et al. CCR6 as a mediator of immunity in the lung and gut. , 2011, Experimental cell research.
[29] D. Artis,et al. CD4(+) lymphoid tissue-inducer cells promote innate immunity in the gut. , 2011, Immunity.
[30] B. Becher,et al. IL-12 initiates tumor rejection via lymphoid tissue–inducer cells bearing the natural cytotoxicity receptor NKp46 , 2010, Nature Immunology.
[31] J. Tschopp,et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors , 2009, Nature Medicine.
[32] C. Tato,et al. Lymphoid tissue inducer–like cells are an innate source of IL-17 and IL-22 , 2009, The Journal of experimental medicine.
[33] Hiromu Ito,et al. Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model , 2007, The Journal of experimental medicine.
[34] Z. Trajanoski,et al. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.
[35] M. Kleinewietfeld,et al. CCR6 expression defines regulatory effector/memory-like cells within the CD25(+)CD4+ T-cell subset. , 2005, Blood.